A British court rejected Kellogg's arguments in its legal action against the UK government over new regulations preventing it from prominently displaying some of its breakfast cereals in supermarkets due to their sugar content.
Kellogg argued that the UK government's way of measuring the nutritional value of cereal without milk or yogurt is “wrong”.
The new regulations, which come into effect in October, are designed to help tackle childhood obesity and will restrict the promotion of food and drink products that are high in fat, salt, or sugar.
Kellogg noted that it supported the government’s work to tackle obesity, demonstrated by its past efforts to reduce sugar and salt in its cereals.
A Kellogg spokesperson said that while they respect the court's decision and do not intend to appeal, they still believe that cereals should be measured with milk as it is the way most people eat them.
They also raised their concern that the government introduced these regulations without proper parliamentary scrutiny.


Trump Administration Appeals Court Order to Release Hudson Tunnel Project Funding
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations
Yen Slides as Japan Election Boosts Fiscal Stimulus Expectations
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 



